Dio Tree
Tel Aviv, Israel· Est.
Innovative DIO3‑targeting small molecules for ovarian cancer and beyond.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative DIO3‑targeting small molecules for ovarian cancer and beyond.
Oncology
Technology Platform
Novel small‑molecule inhibitors based on a dibromomaleic anhydride scaffold that selectively inhibit the DIO3 enzyme, restoring tumor‑suppressive thyroid hormone activity.
Opportunities
First‑in‑class DIO3 inhibition offers a novel mechanism to target a broad range of aggressive cancers, with potential for combination therapies and expansion beyond ovarian cancer.
Risk Factors
Early‑stage development carries high scientific and regulatory risk; substantial capital will be needed to progress IND‑enabling studies and clinical trials.
Competitive Landscape
Few companies target thyroid hormone metabolism in cancer, giving Dio Tree a differentiated position, though it must compete with established oncology pipelines and emerging metabolic therapies.